文献速递白血病

PTPN6基因在晚期慢性髓系白血病中表观遗传调控机制的研究

Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2017-05-08

研究纳入44例慢性髓系白血病(CML)患者及10名健康志愿者的骨髓或血液样本,并培养KCL22与K562细胞,用去甲基化药物和组蛋白去乙酰化酶抑制剂处理,采用qPCR、甲基化特异性PCR、亚硫酸氢盐测序PCR、Western blotting、共免疫沉淀和染色质免疫沉淀等方法检测。结果显示PTPN6在晚期CML细胞系和患者中下调,而DNMT1、DNMT3A、MECP2、MBD2和HDAC1上调;药物处理可提高PTPN6表达并降低上述分子表达。

要点

  • PTPN6在晚期CML细胞系和患者中表达下调,与疾病进展相关。
  • PTPN6低表达与DNA甲基化相关,并受组蛋白乙酰化调控。
  • HDAC1直接结合PTPN6并参与其调控。

核心结论

  • PTPN6与CML进展相关;PTPN6低表达与DNA甲基化相关并受组蛋白乙酰化调控;HDAC1参与PTPN6的调控。

研究设计与样本

  • 研究检测44例CML患者和10名健康志愿者的骨髓或血液样本,并培养KCL22和K562细胞,用去甲基化药物和组蛋白去乙酰化酶抑制剂处理,采用qPCR、甲基化特异性PCR、亚硫酸氢盐测序PCR、Western blotting、共免疫沉淀和染色质免疫沉淀等方法。

主要发现

  • PTPN6在晚期CML细胞系和患者中下调,而DNMT1、DNMT3A、MECP2、MBD2和HDAC1上调。
  • 5-氮杂胞苷、地西他滨、丙戊酸钠和LBH589处理可提高PTPN6表达,并降低DNMT1、DNMT3A、MECP2、MBD2和HDAC1表达。
  • 免疫沉淀和质谱显示HDAC1直接与PTPN6结合。
  • 染色质免疫沉淀测序显示HDAC1不与PTPN6启动子区结合,而MAPK、AKT、STAT5、JAK2和MYC启动子区均与HDAC1结合。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PTPN6, a tyrosine phosphatase protein, plays a negative role in cell signal transduction and is negatively correlated with tumour formation and growth. However, epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia (CML) remains unclear. This study investigated bone marrow or blood samples from 44 CML patients and 10 healthy volunteers. KCL22 and K562 cells were cultured and treated with demethylation drugs and histone deacetylase inhibitors. Real time quantitative polymerase chain reaction (qPCR), methylation-specific PCR, bisulfite sequencing PCR, Western blotting, co-immunoprecipitation and chromatin immunoprecipitation (ChIP) was performed. PTPN6 was down-regulated in cell lines and patients with advanced phase CML, whereas DNMT1, DNMT3A, MECP2, MBD2 and HDAC1 were up-regulated. Treatment with 5-azacytidine, decitabine, sodium valproate and LBH589 increased PTPN6 expression, but decreased that of DNMT1, DNMT3A, MECP2, MBD2 and HDAC1. Immunoprecipitation and mass spectrometry showed that HDAC1 combined directly with PTPN6. ChIP-seq showed that HDAC1 did not combine with the promoter region of PTPN6, while MAPK, AKT, STAT5, JAK2 and MYC promoter regions all combined with HDAC1. PTPN6 is associated with progression of CML. Low expression level of PTPN6 was associated with DNA methylation and regulated by histone acetylation. HDAC1 participates in the regulation of PTPN6.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang X, Yang L, Liu X, et al. Research on the epigenetic regulation mechanism of the PTPN6 gene in advanced chronic myeloid leukaemia. Br J Haematol. 2017. PMID: 28480959. doi:10.1111/bjh.14739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。